For each tobacco use and disease category, we calculated crude death rates per 1000 person-years (the sum of years contributed by all participants in the tobacco use category): We then estimated HRs adjusted for age only, then for age, race/ethnicity, marital status, education, income, region, and survey year
and available data does not provide enough information for CMS to determine whether Leukine has unique circumstances that would prompt an increase in the applicable percentage, we are not proposing an increase in the applicable percentage for the drug at this time
In the CY 2023 PFS final rule (87 FR 69723), we discussed the applicability of the JW and JZ modifiers to drugs that are not administered by the billing supplier, including drugs furnished through a covered item of DME that may be administered by the beneficiary
In a recent policy review of 180 countries that are signatories to WHO FCTC, we found that only a handful of countries have addressed ST control at par with cigarettes [93]